The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...

The complement system has more than 50 soluble and membrane-bound proteins. In innate and adaptive immunity, complement is essential for eliminating foreign pathogens and apoptotic cells. It is also ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...